# A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations

> **NCT00165789** · PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 75 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** E2007

## Key facts

- **NCT ID:** NCT00165789
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-02
- **Final completion:** 2006-09
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2015-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165789, "A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00165789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*